Skip to content
Homepage
Author:
enVVeno Medical Corporation
Posted Date:
July 7, 2026
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
enVVeno Medical Corporation
July 7, 2026
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
enVVeno Medical Corporation
June 22, 2026
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
enVVeno Medical Corporation
June 2, 2026
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor “What This Means” Segment
enVVeno Medical Corporation
May 12, 2026
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
enVVeno Medical Corporation
May 7, 2026
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
enVVeno Medical Corporation
April 29, 2026
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
enVVeno Medical Corporation
March 27, 2026
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
enVVeno Medical Corporation
February 4, 2026
